Decreased expression and aberrant methylation of RASSF5A correlates with malignant progression of gastric cardia adenocarcinoma

Molecular Carcinogenesis

Volumn 54, Issue 12, 2015, Pages 1722-1733

  Han, Lijie ^a,b   Dong, Zhiming ^a   Wang, Cong ^a   Guo, Yanli ^a   Shen, Supeng ^a   Kuang, Gang ^a   Guo, Wei ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b CANGZHOU CENTRAL HOSPITAL   (China)

Author keywords

Expression; Gastric cardia adenocarcinoma; Methylation; RASSF5

Indexed keywords

RAS PROTEIN; RASSF5A PROTEIN; RASSF5C PROTEIN; UNCLASSIFIED DRUG; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; RASSF5 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CARDIA CARCINOMA; CONTROLLED STUDY; CPG ISLAND; DOWN REGULATION; FEMALE; FOLLOW UP; GASTRIC CARDIA ADENOCARCINOMA; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADENOCARCINOMA; CARDIA; DISEASE COURSE; DNA METHYLATION; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR;

ADENOCARCINOMA; ADULT; AGED; CARDIA; CPG ISLANDS; DISEASE PROGRESSION; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MONOMERIC GTP-BINDING PROTEINS; PROMOTER REGIONS, GENETIC; STOMACH NEOPLASMS;

EID: 84944583572     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22245     Document Type: Article

References (40)

1. Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Semin Oncol 2004; 31:450-464.
2. Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol 2006; 12:17-20.
3. Ma JL, Zhang L, Brown LM, et al. Fifteen-year effects of helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst 2012; 104:488-492.
4. Gao Y, Hu N, Han X, et al. Family history of cancer and risk for esophageal and gastric cancer in Shanxi, China. BMC Cancer 2009; 9:-269.
5. Cully M, Downward J. SnapShot: Ras Signaling. Cell 2008; 133:1292-1292.
6. Tanaka T, Rabbitts TH. Interfering with protein-protein interactions: Potential for cancer therapy. Cell Cycle 2008; 7:1569-1574.
7. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta 2009; 1796:114-128.
8. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci 2007; 120:3163-3172.
9. Guo W, Dong Z, Chen Z, et al. Aberrant CpG Island hypermethylation of RASSF1A in gastric cardia adenocarcinoma. Cancer Invest 2009; 27:459-465.
10. Guo W, Cui L, Wang C, et al. Decreased expression of RASSF1A and up-regulation of RASSF1C is associated with esophageal squamous cell carcinoma. Clin Exp Metastasis 2014; 31:521-533.
11. Vavvas D, Li X, Avruch J, Zhang XF. Identification of Nore1 as a potential Ras effector. J Biol Chem 1998; 273:5439-5442.
12. Tommasi S, Dammann R, Jin SG, Zhang XF, Avruch J, Pfeifer GP. RASSF3 and NOR E1: Identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1. Oncogene 2002; 21:2713-2720.
13. Hesson L, Dallol A, Minna JD, Maher ER, Latif F. NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene 2003; 22:947-954.
14. Shinmura K, Tao H, Nagura K, et al. Suppression of hydroxyurea-induced centrosome amplification by NORE1A and down-regulation of NORE1A mRNA expression in non-small cell lung carcinoma. Lung Cancer 2011; 71:19-27.
15. Lee CK, Lee JH, Lee MG, et al. Epigenetic inactivation of the NORE1 gene correlates with malignant progression of colorectal tumors. BMC Cancer 2010; 10:-577.
16. Calvisi DF, Donninger H, Vos MD, et al. NORE1A tumor suppressor candidate modulates p21CIP1 via p53. Cancer Res 2009; 69:4629-4637.
17. Geli J, Kogner P, Lanner F, et al. Assessment of NORE1A as a putative tumor suppressor in human neuroblastoma. Int J Cancer 2008; 123:389-394.
18. Djos A, Martinsson T, Kogner P, Carén H. The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma. Mol Cancer 2012; 11:40.
19. V600E mutations in thyroid tumors. Lab Invest 2005; 85:1065-1075.
20. Irimia M, Fraga MF, Sanchez-Cespedes M, Esteller M. CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer. Oncogene 2004; 23:8695-8699.
21. Steinmann K, Sandner A, Schagdarsurengin U, Dammann RH. Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma. Oncol Rep 2009; 22:1519-1526.
22. Geli J, Kiss N, Lanner F, et al. The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma. Endocr Relat Cancer 2007; 14:125-134.
23. Lorente A, Mueller W, Urdangarín E, et al. RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs. Brain Pathol 2009; 19:279-292.
24. Macheiner D, Heller G, Kappel S, et al. NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma. J Hepatol 2006; 45:81-89.
25. Macheiner D, Gauglhofer C, Rodgarkia-Dara C, et al. NORE1B is a putative tumor suppressor in hepatocarcinogenesis and may act via RASSF1A. Cancer Res 2009; 69:235-242.
26. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998; 85:1457-1459.
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25:402-408.
28. Umemoto M, Yokoyama Y, Sato S, Tsuchida S, Al-Mulla F, Saito Y. Carbonyl reductase as a significant predictor of survival and lymph node metastasis in epithelial ovarian cancer. Br J Cancer 2001; 85:1032-1036.
29. Sasaki M, Anast J, Bassett W, Kawakami T, Sakuragi N, Dahiya R. Bisulfite conversion-specific and methylation-specific PCR: A sensitive technique for accurate evaluation of CpG methylation. Biochem Biophys Res Commun 2003; 309:305-309.
30. Li LC, Dahiya R. MethPrimer: Designing primers for methylation PCRs. Bioinformatics 2002; 18:1427-1431.
31. Zhou CZ, Qiu GQ, Zhang F, He L, Peng ZH. Loss of heterozygosity on chromosome 1 in sporadic colorectal carcinoma. World J Gastroenterol 2004; 10:1431-1435.
32. Ragnarsson G, Eiriksdottir G, Johannsdottir JT, Jonasson JG, Egilsson V, Ingvarsson S. Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. Br J Cancer 1999; 79:1468-1474.
33. Steiner G, Cairns P, Polascik TJ, et al. High-density mapping of chromosomal arm 1q in renal collecting duct carcinoma: Region of minimal deletion at 1q32.1-32.2. Cancer Res 1996; 56:5044-5046.
34. Chen J, Lui WO, Vos MD, et al. The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas. Cancer Cell 2003; 4:405-413.
35. Ghavifekr Fakhr, Farshdousti M, Hagh M, Shanehbandi D, Baradaran B. DNA methylation pattern as important epigenetic criterion in cancer. Genet Res Int. 2013; 2013:317569.
36. Di Gioia S, Bianchi P, Destro A, et al. Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver. BMC Cancer 2006; 6:89.
37. Hesson L, Bièche I, Krex D, et al. Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene 2004; 23:2408-2419.
38. Chow LS, Lo KW, Kwong J, Wong AY, Huang DP. Aberrant methylation of RASSF4/AD037 in nasopharyngeal carcinoma. Oncol Rep 2004; 12:781-787.
39. Lázcoz P, Muñoz J, Nistal M, Pestaña A, Encío I, Castresana JS. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma. BMC Cancer 2006; 6:254.
40. Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008; 358:1118-1128.